tickdelta
Sign in
Screener / SEC EDGAR /CIK 0000096943 /10-K filed Feb 27, 2026, compared with Feb 28, 2025 /Numbers from the XBRL of the 10-Ks
Health care peers:
ICUICONTFXPRVAENOVRDNT
NYSE Health care · Medical Instruments

Teleflex Inc TFX

TFX quote by TradingView

Teleflex Incorporated is referred to herein as “we,” “us,” “our,” “Teleflex” and the “Company.” 10-K, Item 1

Employees
15,500
Headquarters
Wayne, PA
CEO
Jason R. Weidman
Next results
around Jan 7, 2027
Compare with peers Embed

Where each dollar of revenue went, FY2024

Revenue of $1.7B through the costs to a net profit of $69.7M · income statement of the 10-K

6% operating margin
Revenue to Gross profit: $1.0BRevenue to Cost of revenue: $662.2MGross profit to Operating profit: $103.7MGross profit to Operating expenses: $933.7MOperating profit to Net profit: $69.7MOperating profit to Interest, tax, other: $34.0MOperating expenses to R&D: $109.0MOperating expenses to Sales, admin & other: $824.7M Revenue: $1.7B REVENUE $1.7B −1% Y/Y Gross profit: $1.0B · 61% margin GROSS PROFIT $1.0B 61% margin · +0% Y/Y Cost of revenue: $662.2M · 39% of revenue COST OF REVENUE $662.2M 39% of revenue Operating profit: $103.7M · 6% margin OPERATING PROFIT $103.7M 6% margin · −60% Y/Y Operating expenses: $933.7M · 55% of revenue OPERATING EXPENSES $933.7M 55% of revenue Net profit: $69.7M · 4% margin NET PROFIT $69.7M 4% margin · −80% Y/Y Interest, tax, other: $34.0M · 2% of revenue INTEREST, TAX, OTHER $34.0M 2% of revenue R&D: $109.0M · 6% of revenue R&D $109.0M 6% of revenue Sales, admin & other: $824.7M · 49% of revenue SALES, ADMIN & OTHER $824.7M 49% of revenue
Gross profit $1.0B 61% margin · +0% Y/Y
Operating profit $103.7M 6% margin · −60% Y/Y
Net profit $69.7M 4% margin · −80% Y/Y
The full income statement, year by year

TFX among Health care peers

Six ratios from the latest 10-K. Each corner is the share of 154 peers the company is above, not a score.

Compare
Revenue growth: 17.2%, above 70% of 154 peers (their median 10.4%) REVENUE GROWTH 17.2% · above 70% Gross margin: 58.3%, above 40% of 107 peers (their median 63.8%) GROSS MARGIN 58.3% · above 40% Operating margin: 9.4%, above 49% of 138 peers (their median 10.2%) OPERATING MARGIN 9.4% · above 49% Net margin: 13.5%, above 70% of 153 peers (their median 6.7%) NET MARGIN 13.5% · above 70% FCF margin: 10.8%, above 51% of 144 peers (their median 9.9%) FCF MARGIN 10.8% · above 51% Return on capital: 5.5%, above 20% of 89 peers (their median 9.2%) RETURN ON CAPITAL 5.5% · above 20%
TFX Peer median Below the median

What changed

7 new risk paragraphs and 3 accounting facts worth reading about. 10-K filed Feb 27, 2026 against Feb 28, 2025.

Risk factors
7 new paragraphs, nothing like them in the previous 10-K
10-K Item 1A
Receivables growing faster than revenue
Receivables +52.4% ($226.7M to $345.6M) vs revenue +17.2% ($1.7B to $2.0B), +35.2 pts apart
10-K · XBRL
Inventory growing faster than revenue
Inventory +31.8% ($306.8M to $404.4M) vs revenue +17.2% ($1.7B to $2.0B), +14.6 pts apart
10-K · XBRL
Critical audit matters changed
New this year: Acquisition of the VI Business - Valuation of Customer Relationships and Intellectual Property (“As described in Note 4 to the consolidated financial statements, in the third quarter of 2025, the Company completed the acquisition of substantially all of the VI Business for a net initial cash payment of $825.2 million. Of the acquired intangible assets, $177.0 million of customer relationships a”). No longer listed: Goodwill Impairment Assessments - Interventional Urology North America Reporting Unit
10-K · XBRL
Accounting checks
8 other checks clear, 3 worth a look
10-K · XBRL
Insiders
No open-market buys in the last 90 days
Form 4
Filings
2 in the last 30 days
EDGAR

Each row opens the detail with the quote and the filing. A row is a change worth reading, not a verdict.

Accounting checks

11 checks on the latest 10-K. Checks, not verdicts.

How it works

3facts worth reading about the other 8 checks found nothing to note

  • Receivables growing faster than revenue
    Receivables +52.4% ($226.7M to $345.6M) vs revenue +17.2% ($1.7B to $2.0B), +35.2 pts apart
  • Inventory growing faster than revenue
    Inventory +31.8% ($306.8M to $404.4M) vs revenue +17.2% ($1.7B to $2.0B), +14.6 pts apart
  • Critical audit matters changed
    New this year: Acquisition of the VI Business - Valuation of Customer Relationships and Intellectual Property (“As described in Note 4 to the consolidated financial statements, in the third quarter of 2025, the Company completed the acquisition of substantially all of the VI Business for a net initial cash payment of $825.2 million. Of the acquired intangible assets, $177.0 million of customer relationships a”). No longer listed: Goodwill Impairment Assessments - Interventional Urology North America Reporting Unit
  • Cash from operations $96.7M vs net income −$905.6M (FY ending Dec 31, 2025)
7 more checks with nothing to note
  • Same auditor in both 10-Ks: PricewaterhouseCoopers LLP
  • No statement of substantial doubt about going concern
  • No 8-K item 4.02 in the last 2 years
  • No NT 10-K or NT 10-Q in the last 2 years
  • No sentence in the 10-K concludes that controls were not effective because of a material weakness
  • No 8-K item 2.06 in the last 2 years
  • No 8-K item 1.03 in the last 2 years

In their words

7 paragraphs in Risk Factors that were not in the 10-K filed Feb 28, 2025. Quoted as filed.

All 7 new paragraphs
  1. Item 1A · new paragraph · not in the 10-K filed Feb 28, 2025 10-K, ITEM 1A
    The strategic transformation that we are currently implementing may not have the intended results and may be harmful to our business. In February 2025, we announced our intention to undertake a strategic transformation of the organization. In accordance with this strategy, on December 9, 2025, with the simultaneous execution of…
  2. Item 1A · new paragraph · not in the 10-K filed Feb 28, 2025 10-K, ITEM 1A
    On January 8, 2026, we announced that Stuart Randle, a member of our board of directors, has been appointed Interim President and Chief Executive Officer, succeeding our prior Chairman, President and CEO, and that Dr. Stephen Klasko, at that time our Lead Director, has been named Chairman of the Board. We also announced that the board…

New risk paragraphs, against peers

Latest 10-K of each, Health care companies closest in revenue

Paragraphs in Risk Factors with nothing like them in the company's 10-K the year before. A count of text, not of risk.

Financial performance

Last 4 fiscal years · 10-K XBRL

All years
MetricFY2022FY2023FY2024FY2025
Revenue$2.8B$1.7B$1.7B$2.0B
Net income$363.1M$356.3M$69.7M−$905.6M
Operating cash flow$342.8M$206.1M$301.9M$96.7M
Free cash flow$263.6M$159.7M$211.4M$1.4M

Revenue, FY2016 to FY2025

Ten fiscal years, each from its own 10-K · XBRL · USD

$2.0B ▲ 17.2% in FY2025

FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Every number, year by year

Recent filings

2 filings in the last 30 days · SEC EDGAR

All filings

About the company

Teleflex Inc, Wayne, PA · from the 10-K filed Feb 27, 2026

Teleflex Incorporated is referred to herein as “we,” “us,” “our,” “Teleflex” and the “Company.” Teleflex is a global provider of medical technology products that enhance clinical benefits, improve patient and provider safety and reduce total procedural costs. We primarily design, develop, manufacture and supply single-use medical devices used by hospitals and healthcare providers for common diagnostic and therapeutic procedures in critical care and surgical applications. We market and sell our products to hospitals and healthcare providers worldwide through a combination of our direct sales force and distributors.

Headquarters
Wayne, PA
Country
United States
Reports in
USD
Listed on
NYSE
Fiscal year ends
December 31
Last results
Nov 5, 2026
Incorporated in
DE

Employees, at the top of the page: "As of December 31, 2025, we employed approximately 15,500 employees, including 3,700 employees in the U" (10-K). Address and exchange: SEC's company file.

Email alerts

Sources

The 10-K filed Feb 27, 2026 (open at SEC), compared with the 10-K filed Feb 28, 2025. Numbers from the XBRL of the 10-Ks; filings from SEC EDGAR.

Work with it: Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/TFX/export.csv") into a cell.

Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.